Residency · Residency · General Surgery
Venous Thromboembolism Prophylaxis in Surgery
Introduction
Venous thromboembolism (VTE), encompassing deep venous thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of preventable morbidity and mortality in surgical patients. Without prophylaxis, the incidence of DVT after major surgery ranges from 15 to 40%, and PE accounts for approximately 10% of all in-hospital deaths. Risk stratification and appropriate prophylaxis are core competencies for every surgical resident, and VTE prevention is a key quality measure in surgical care.
Pathophysiology: Virchow's Triad
The three components of Virchow's triad explain the pathogenesis of VTE in surgical patients. Venous stasis results from immobility, anesthesia-induced venodilation, and venous compression from positioning, tumor mass, or pregnancy. Endothelial injury occurs through surgical dissection, venous manipulation, prior DVT, central venous catheters, and trauma. Hypercoagulability is driven by the inflammatory response to surgery, malignancy, inherited thrombophilias, estrogen therapy, dehydration, and obesity.
Risk Stratification
Caprini Risk Assessment Model
The Caprini score is the most widely validated surgical VTE risk assessment tool. It assigns points based on patient and procedure-related risk factors. One-point factors include age 41 to 60, minor surgery, BMI above 25, varicose veins, pregnancy or postpartum state, oral contraceptives or hormone replacement therapy, sepsis, serious lung disease, abnormal pulmonary function, congestive heart failure, history of inflammatory bowel disease, and medical patient on bed rest. Two-point factors include age 61 to 74, arthroscopic surgery, major open surgery exceeding 45 minutes, laparoscopic surgery exceeding 45 minutes, malignancy, bed rest exceeding 72 hours, immobilizing plaster cast, and central venous access. Three-point factors include age above 75, history of DVT or PE, family history of VTE, Factor V Leiden, prothrombin 20210A mutation, lupus anticoagulant, anticardiolipin antibodies, elevated homocysteine, heparin-induced thrombocytopenia, and other thrombophilias. Five-point factors include stroke within 1 month, multiple trauma, acute spinal cord injury, and major orthopedic surgery.
The resulting risk categories guide prophylaxis recommendations:
| Caprini Score | Risk Level | VTE Risk (without prophylaxis) | Recommended Prophylaxis |
|---|---|---|---|
| 0 | Very low | <0.5% | Early ambulation only |
| 1–2 | Low | ~1.5% | Mechanical (IPC devices) |
| 3–4 | Moderate | ~3% | Pharmacologic (LMWH or UFH) ± mechanical |
| ≥5 | High | ~6% | Combined pharmacologic + mechanical; consider extended prophylaxis |
Very low risk patients with 0 points require only early ambulation. Low risk patients with 1 to 2 points receive mechanical prophylaxis with intermittent pneumatic compression devices. Moderate risk patients with 3 to 4 points receive pharmacologic prophylaxis with LMWH or UFH and/or mechanical prophylaxis. High risk patients with 5 or more points receive combined pharmacologic and mechanical prophylaxis, with extended prophylaxis considered.
<image>Caprini risk assessment model scoring chart organized as a visual point-based table with risk factors grouped by point value (1, 2, 3, and 5 points), risk categories with corresponding VTE incidence rates, and recommended prophylaxis strategies for each risk level including early ambulation, mechanical prophylaxis, and pharmacologic options</image>
Mechanical Prophylaxis
Intermittent pneumatic compression devices (IPCDs) sequentially compress the lower extremities to enhance venous return and stimulate endogenous fibrinolysis. They are the first-line option for patients at risk of bleeding. Graduated compression stockings provide 18 to 23 mmHg gradient compression and offer modest benefit alone, often serving as an adjunct to pharmacologic prophylaxis. They are contraindicated in peripheral arterial disease with an ankle-brachial index below 0.5. Early ambulation is the most basic and important thromboprophylactic measure and should be initiated as early as possible after surgery. The main limitation of mechanical prophylaxis is that devices must be worn consistently to be effective, and nursing compliance and patient tolerance are common barriers.
Pharmacologic Prophylaxis
Low-Molecular-Weight Heparin (LMWH)
Enoxaparin is the most commonly used LMWH, dosed at 40 mg subcutaneously daily for standard prophylaxis or 30 mg subcutaneously every 12 hours for high-risk patients or major orthopedic surgery. Dalteparin is dosed at 5000 units subcutaneously daily. Advantages of LMWH include predictable pharmacokinetics, once-daily dosing, lower HIT risk than UFH, and no need for routine monitoring. Disadvantages include renal clearance requiring dose reduction or substitution with UFH when creatinine clearance falls below 30 mL/min, a longer half-life making reversal more difficult, and higher cost.
Unfractionated Heparin (UFH)
UFH is dosed at 5000 units subcutaneously every 8 to 12 hours, with every-8-hour dosing potentially more effective in high-risk patients. Its advantages include a short half-life, full reversibility with protamine, safety in renal insufficiency, and low cost. Disadvantages include higher HIT risk, variable bioavailability, and the need for more frequent dosing which may reduce compliance.
Direct Oral Anticoagulants (DOACs)
Rivaroxaban at 10 mg daily and apixaban at 2.5 mg twice daily are approved for VTE prophylaxis after hip and knee arthroplasty. Evidence is growing for their use in general surgery and cancer surgery, though they are not yet standard first-line agents. Advantages include oral dosing and no monitoring requirement, while disadvantages include cost, limited reversal options with andexanet alfa for factor Xa inhibitors, and renal clearance concerns.
Fondaparinux
Fondaparinux at 2.5 mg subcutaneously daily is a synthetic factor Xa inhibitor that serves as an alternative for patients with HIT, as it has no cross-reactivity with HIT antibodies. Its long half-life of 17 to 21 hours requires caution in renal insufficiency.
Timing of Initiation
LMWH is typically initiated 2 hours preoperatively or 6 to 12 hours postoperatively, varying by regional practice and bleeding risk. UFH follows a similar schedule of 2 hours preoperatively or 6 to 12 hours postoperatively. For patients receiving neuraxial anesthesia, LMWH should be held for 12 hours before and 4 hours after epidural placement or removal, while UFH is held 4 to 6 hours before.
Special Populations
Cancer Surgery
Surgical patients with active malignancy face 2 to 3 times higher VTE risk. Extended prophylaxis with 4 weeks of LMWH after major abdominal or pelvic cancer surgery is recommended, supported by the ENOXACAN II trial and ACCP guidelines. The PERIOP-2 trial provides additional support for extended LMWH prophylaxis in cancer surgery.
Bariatric Surgery
Obese patients have higher baseline VTE risk, and optimal prophylaxis dosing is debated. Weight-based LMWH dosing is commonly used, with enoxaparin 40 mg twice daily for BMI above 40 or 60 mg twice daily for BMI above 50. Combined pharmacologic and mechanical prophylaxis is recommended.
Trauma
The trauma population is at high VTE risk, particularly with polytrauma, spinal cord injury, pelvic fractures, and traumatic brain injury. Pharmacologic prophylaxis should be initiated as soon as bleeding risk allows, typically 24 to 72 hours after injury or surgery. Mechanical prophylaxis is used until pharmacologic agents can be safely started. IVC filters are reserved for patients with documented VTE who have absolute contraindications to anticoagulation, with retrievable filters preferred. Prophylactic IVC filters are not recommended.
Orthopedic Surgery
Total hip and knee arthroplasty and hip fracture surgery require extended prophylaxis for 28 to 35 days postoperatively. Options include LMWH, fondaparinux, apixaban, rivaroxaban, and aspirin for low-risk patients.
<image>Decision algorithm for VTE prophylaxis in surgical patients showing the stepwise approach: assess Caprini score, determine bleeding risk, select appropriate mechanical and/or pharmacologic prophylaxis, adjust for special populations (cancer, bariatric, trauma, orthopedic), and determine duration of prophylaxis with extended prophylaxis indications highlighted</image>
Heparin-Induced Thrombocytopenia (HIT)
Type I HIT is a non-immune, mild thrombocytopenia occurring within 1 to 2 days of heparin exposure that is self-limited and requires no treatment. Type II HIT is immune-mediated, caused by anti-PF4/heparin antibodies, and occurs 5 to 14 days after heparin exposure. Despite the thrombocytopenia, it is paradoxically associated with both arterial and venous thrombosis. Diagnosis uses the 4T score for clinical probability assessment, confirmed by anti-PF4/heparin ELISA and serotonin release assay (SRA). Management requires immediately discontinuing all heparin products and initiating a non-heparin anticoagulant such as argatroban for patients with hepatic metabolism or bivalirudin for its shorter half-life. Warfarin must not be used alone due to the risk of venous limb gangrene, and transition to warfarin should occur only after platelet recovery.
Bleeding Risk Assessment
Every patient requires balancing VTE risk against bleeding risk. High bleeding risk procedures include craniotomy, spinal surgery, major hepatic resection, and procedures with high intraoperative blood loss. Patient factors that increase bleeding risk include active hemorrhage, severe thrombocytopenia with platelets below 50,000, coagulopathy, and concurrent anticoagulation. For patients at high bleeding risk, mechanical prophylaxis alone is used initially, with pharmacologic prophylaxis added when bleeding risk diminishes, typically 24 to 72 hours postoperatively.
Clinical Pearls
VTE risk assessment using the Caprini score should be performed on every surgical patient at admission. Combined pharmacologic and mechanical prophylaxis is recommended for high-risk patients with a Caprini score of 5 or greater. Extended prophylaxis for 4 weeks with LMWH is the standard after major abdominal or pelvic cancer surgery. HIT Type II is a prothrombotic state despite the thrombocytopenia, requiring immediate discontinuation of all heparin and initiation of a non-heparin anticoagulant. Prophylactic IVC filters are not recommended because they do not reduce PE mortality and carry significant complications.
References
- Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S-e277S.
- Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2-3):70-78.
- Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975-980.
- Pannucci CJ, Swistun L, MacDonald JK, et al. Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients. Ann Surg. 2017;265(6):1094-1103.
